Yavuz Köksal

Yavuz Köksal

Auto-generated profile, based on publicly available information

Yavuz Köksal

SELÇUK ÜNİVERSİTESİ, TIP FAKÜLTESİ

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
YKYavuz Köksal
Yavuz Köksal
HTHatice Toy
Hatice Toy
BTBeril Talim
Beril Talim
EUEkrem Unal
Ekrem Unal
ZAZuhal Akçören
Zuhal Akçören
MCMustafa Cengiz
Mustafa Cengiz
Merkel cell carcinoma, a rare tumor of the skin with aggressive behavior, is usually fatal when advanced disease is present. Merkel cell carcinoma occurs mostly in white race between 60 and 80 years of age, however, it can occur in any races and ages. It is extremely rare in children. We present here a Merkel cell carcinoma in a boy. Its features and treatment modalities were discussed in the literature light.

1 January 2007 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
YKYavuz Koksal
Yavuz Koksal
UCUmran Caliskan
Umran Caliskan
CUCanan Ucar
Canan Ucar
MYMuslim Yurtcu
Muslim Yurtcu
HAHasibe Artac
Hasibe Artac
IRIsmail Reisli
Ismail Reisli
Ataxia-telangiectasia is an autosomal recessive disease characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, high incidence of cancer, and increased sensitivity to ionizing radiation. The authors report a case of dysgerminoma in a child with high alpha-fetoprotein, CA125 and beta-human chorionic gonadotropin, who has been followed-up for ataxia-telangiectasia for 2 years.

1 October 2008 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
EUEkrem Unal
Ekrem Unal
YKYavuz Koksal
Yavuz Koksal
OCOmer Cimen
Omer Cimen
YPYahya Paksoy
Yahya Paksoy
LTLema Tavli
Lema Tavli

1 December 2005 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
YKYavuz Köksal
Yavuz Köksal
AVAli Varan
Ali Varan
GKGülsev Kale
Gülsev Kale
FTFeridun Cahit Tanyel
Feridun Cahit Tanyel
MBMünevver Büyükpamukçu
Münevver Büyükpamukçu
Bilateral cystic adrenal neuroblastoma is an unusual variant of neuroblastoma, and only two cases have been reported in the neonatal period until now. The authors describe a newborn with splenic and hepatic involvement of bilateral adrenal cystic neuroblastoma.

1 January 2004 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
YKYavuz Koksal
Yavuz Koksal
IRIsmail Reisli
Ismail Reisli
EGEngin Gunel
Engin Gunel
UCUmran Caliskan
Umran Caliskan
ABAlmila Bulun
Almila Bulun
GKGulsev Kale
Gulsev Kale
Granulosa cell tumor of the ovary is a rare form of ovarian cancer in children. An 11-year-old girl was admitted with complaints of galactorrhea and abdominal mass. Abdomino-pelvic ultrasound and computed tomography revealed an ovarian tumor. Her prolactine and estradiol levels were increased but luteinizing hormone and follicle-stimulating hormone were decreased. An exploratory laparotomy revealed a giant solid mass, which was completely removed and determined as juvenile granulosa cell tumor. The clinical, hormonal, and radiological findings and the therapy of galactorrhea associated with granulosa cell tumor in a child are discussed. To our knowledge, this is first time it has been described in childhood.

1 January 2007 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
YKYavuz Köksal
Yavuz Köksal
AVAli Varan
Ali Varan
GAG. Burca Aydin
G. Burca Aydin
NSNeriman Sari
Neriman Sari
NYNalan Yazici
Nalan Yazici
MBMünevver Büyükpamukçu
Münevver Büyükpamukçu
The aim of this study was to determine the efficacy of immunization against hepatitis A and B infections with "rapid" or "accelerated" schedules in children with cancer receiving chemotherapy. Fifty-one children were recruited to receive either vaccination schedule, in the "rapid vaccination schedule"; hepatitis B (group I) or combined hepatitis A/B vaccines (group III) were administered at months 0, 1, 2, and 12; in the "accelerated vaccination schedule," hepatitis B (group II) or combined hepatitis A/B (group IV) vaccines were administered on days 0, 7, 21, and 365 intramuscularly. The seroconversion rates at months 1 and 3 were 35.7 and 57.1% in group I and 25 and 18.8% in group II, respectively. Group I developed higher seroconversion rates at month 3. In group III the seroconversion rates for hepatitis B at months 1 and 3 were 54.5 and 60% and in group IV 50 and 70%, respectively. For hepatitis A, the seroconversion rates at months 1 and 3 were 81.8 and 90% in group III and 80 and 88.9% in group IV, respectively. The accelerated vaccination schedule seems to have no advantage in children receiving cancer chemotherapy except for high antibody levels at month 1. In conclusion, the accelerated vaccination schedules are not good choices for cancer patients. The combined hepatitis A/B vaccine is more effective than monovalent vaccine in cancer patients, which probably can be explained by an adjuvant effect of the antigens. The seroconversion of hepatitis A by the combined hepatitis A/B vaccination is very good in cancer patients.